Last updated: February 19, 2026
Deferasirox, an oral iron chelator used to treat chronic iron overload related to blood transfusions, is supplied by several manufacturers and generic producers globally. Market presence, manufacturing capabilities, and regulatory approvals vary among suppliers.
Leading Manufacturers
| Company |
Headquarters |
Market Role |
Key Notes |
| Novartis |
Switzerland |
Original patent holder |
Introduced deferasirox under the brand name Exjade in 2005; launched Jadenu as a tablet formulation in 2017. |
| Cipla |
India |
Major generic producer |
Offers deferasirox tablets; approved in multiple regions including India and South Africa. |
| Dr. Reddy’s Laboratories |
India |
Generic manufacturer |
Supplies generic deferasirox; approved in the US, India, and other markets. |
| Mylan (now part of Viatris) |
USA |
Generic producer |
Provides deferasirox in tablet form; approved in the US and other countries. |
| Zydus Cadila |
India |
Generic producer |
Marketed deferasirox in India and some Asian markets. |
Market Dynamics and Regulatory Approvals
- Novartis's Exjade was initially approved by the FDA in 2005. The company’s Jadenu, a tablet formulation, gained FDA approval in 2017, improving patient compliance.
- Generics entered the market post-expiry of exclusivity, starting around 2017. Indian companies like Cipla, Dr. Reddy's, and Zydus Cadila are primary producers.
- Market Accessibility varies by country, influenced by patent laws, local regulatory approvals, and supply chain logistics.
Manufacturing Capabilities
- Novartis maintains R&D and manufacturing facilities across Switzerland, US, and Japan.
- Indian firms primarily produce through technology transfers and local manufacturing agreements, with capacity expanding rapidly.
- Some producers import finished formulations, while others manufacture APIs and perform local formulation.
Supply Chain Considerations
- API sourcing is critical; deferasirox API is produced predominantly in India, China, and Europe.
- Export licenses and quality standards (such as WHO GMP or FDA regulations) impact supply reliability.
- Generic manufacturers often face patent litigation or regulatory challenges in some regions.
Top Suppliers Summary
| Supplier |
Market Focus |
Product Forms |
Regulatory Status |
| Novartis (Exjade/Jadenu) |
Global |
Tablets, dispersible tablets |
Patented, licensed, and proprietary formulations |
| Cipla |
India, Africa, Asia |
Tablets |
Approved in multiple countries; generic equivalent |
| Dr. Reddy’s |
India, US |
Tablets |
US FDA approved; included in WHO prequalification list |
| Mylan |
Global |
Tablets |
FDA approved; widely available in North America and Europe |
| Zydus Cadila |
India |
Tablets |
Approved domestically; expanding export |
Market Share and Pricing
- Original branded products command higher prices, with prices ranging from $10 to $15 per tablet.
- Generic versions typically range between $2 and $8 per tablet, contingent on regional regulations and volume discounts.
- Market share shifts toward generics in regions where patent exclusivity has expired.
References
[1] U.S. Food and Drug Administration. (2017). Jadenu (deferasirox) tablets, for oral use. Retrieved from https://www.fda.gov
[2] MarketWatch. (2022). Deferasirox Market Size, Share & Trends Analysis. Retrieved from https://www.marketwatch.com
[3] Indian Pharmacopoeia Commission. (2020). Guidelines on manufacturing deferasirox in India. Retrieved from https://www.ipc.gov.in
Key Takeaways
- Multiple suppliers provide deferasirox globally, including patents-holders and generic manufacturers.
- Original products from Novartis dominate branded markets; generics are predominant in Asia, Africa, and emerging markets.
- Manufacturing capacity is concentrated in India and Europe, with API sourcing critical for supply stability.
- Regulatory approval timelines differ, influencing product availability in different regions.
- Price competitiveness favors generic suppliers post-patent expiry.
FAQs
1. Which company originally developed deferasirox?
Novartis developed and launched deferasirox under the brand name Exjade in 2005.
2. Are generic versions approved globally?
No. Generic approvals depend on regional regulatory agencies; they are approved in many countries but may not have FDA approval unless through an abbreviated new drug application (ANDA).
3. How does patent expiration affect supply?
Patent expiration allows generic manufacturers to produce and market deferasirox, generally lowering prices and increasing supply options.
4. What are common formulations of deferasirox?
Oral tablets and dispersible tablets, with newer formulations like Jadenu offering improved bioavailability and patient compliance.
5. Who are the major API suppliers for deferasirox?
India, China, and Europe are primary API producers, with manufacturing facilities meeting global quality standards.
[1] U.S. Food and Drug Administration. (2017). Jadenu (deferasirox) tablets, for oral use.
[2] MarketWatch. (2022). Deferasirox Market Size, Share & Trends Analysis.
[3] Indian Pharmacopoeia Commission. (2020). Guidelines on manufacturing deferasirox in India.
